- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07938606
MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)
A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Pediatric Patients Aged 6 to 12 Years With Moderate to Severe Atopic Dermatitis
A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis
Primary Objective:
To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Ma
- Numero di telefono: 13601305676
- Email: bch_maleen2021@126.com
Luoghi di studio
-
-
-
Shanghai, Cina
- Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
-
Contatto:
- Chao Deng
- Numero di telefono: 15712950928
- Email: chao.deng@mabgeek.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Aged ≥6 years and <12 years (calculated based on the date of ICF signature), regardless of gender, with a baseline body weight ≥15 kg and <60 kg.
- Diagnosed with atopic dermatitis (AD) according to the American Academy of Dermatology (AAD) consensus criteria (2014), with a history of AD or eczema diagnosed for ≥6 months prior to screening (with disease onset defined as the date of first symptom appearance).
- Inadequate response to topical medications within 12 months prior to screening, or medically unsuitable for topical medication therapy.
- Participants and/or their parents or legal guardians voluntarily provide written informed consent. For participants aged ≥6 years and <8 years, signing an informed consent form is not required, but an assent form must be completed. Participants must be able to communicate effectively with the investigator and comply with protocol-required follow-up visits.
Exclusion Criteria:
- Unable to undergo subcutaneous injection
- Have other active skin diseases that may affect AD evaluation (such as psoriasis or lupus erythematosus);
- Have diseases that may require systemic glucocorticoid or immunosuppressant treatment;
- Patients with ocular diseases deemed unsuitable for enrollment by the investigator;
- Received allergen-specific immunotherapy within 6 months before dosing; Stopped all topical medications less than 2 weeks before dosing, including topical glucocorticoids, topical calcineurin inhibitors, antibiotic compound creams, topical TCM therapy;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: A:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
Sperimentale: B:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
Sperimentale: C:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
|
Sperimentale: D:MG-K10 humanized monoclonal antibody injection
|
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of adverse events
Lasso di tempo: Up to Week 24
|
Incidence and severity of AEs, plus abnormality rates/severity of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG. |
Up to Week 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percent of Participants with Investigator's Global Assessment (IGA) 0/1 and ≥2-Point Improvement
Lasso di tempo: Each assessment visit through Week 16
|
Proportion achieving IGA score 0 or 1 AND ≥2-point reduction vs. baseline |
Each assessment visit through Week 16
|
|
Percent of Participants with ≥2-Point IGA Improvement
Lasso di tempo: Through Week 16
|
Proportion with IGA reduction ≥2 points vs. baseline |
Through Week 16
|
|
Percent of Participants Achieving EASI-50, EASI-75, or EASI-90
Lasso di tempo: Through Week 16
|
Proportion with ≥50%/75%/90% EASI reduction vs. baseline |
Through Week 16
|
|
Change in Lesion Body Surface Area (BSA)
Lasso di tempo: Through Week 16
|
Change in lesion body surface area |
Through Week 16
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie genetiche, congenite
- Malattie del sistema immunitario
- Ipersensibilità, immediata
- Ipersensibilità
- Malattie della pelle
- Malattie della pelle, genetiche
- Malattie della pelle, eczematose
- Dermatite
- Malattie e anomalie congenite, ereditarie e neonatali
- Malattie della pelle e del tessuto connettivo
- Dermatite, atopica
- Agenti dermatologici
- Azioni farmacologiche
- Azioni e usi chimici
- Usi terapeutici
- Emollienti
Altri numeri di identificazione dello studio
- MG-K10-AD-007
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .